The potential of secretogranin V as a prognostic biomarker in non-small cell lung cancer

Le résumé fourni par la source

Recent studies indicate that Secretogranin V (SCG5) is aberrantly expressed in various cancers and may be linked to tumor progression and prognosis. This study aims to evaluate the potential of SCG5 as a prognostic biomarker for non-small cell lung cancer (NSCLC). We employed a combination of bioinformatics analysis, Western blotting, and immunofluorescence techniques to investigate the role of SCG5 in NSCLC. A comprehensive analysis of TCGA and GEO pan-cancer datasets revealed a consistent upregulation of SCG5 across multiple cancer types. In NSCLC, SCG5 expression was significantly higher in tumor tissues compared to normal lung tissues (p < 0.001). Kaplan-Meier survival analysis demonstrated that patients with elevated SCG5 expression exhibited lower overall survival rates, suggesting a strong association with poor prognosis. Univariate and multivariate COX regression analyses, conducted on both TCGA cases and our collected patient data, confirmed SCG5 as an independent prognostic factor for NSCLC. Furthermore, immune infiltration analysis indicated a significant correlation between SCG5 expression and various immune cell subpopulations, underscoring its potential role as a biomarker for adverse outcomes. Western blot analysis further validated the elevated levels of SCG5 in NSCLC tissues and cell lines compared to their normal counterparts. Based on our findings, we hypothesize that SCG5 may serve as a valuable biomarker for predicting the prognosis of non-small cell lung cancer, thereby guiding future research in the fields of diagnosis, progression, therapy, and prognosis of NSCLC.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.